Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PMV Pharmaceuticals, Inc.PMVP · Entity 7062 | Chief Financial Officer | March 05, 2026 | March 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PMV Pharmaceuticals, Inc.
Report date March 05, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2036-03-05 | Direct | 240,000 |
Reported balance
After 2026-03-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-05 · Grant · Acquired 240,000 · Balance 240,000 F2: Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 73,848 |
Reported balance
Holding disclosure · report date 2026-03-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 73,848 F1: Includes 13,702 shares acquired under the Issuer's Employee Stock Purchase Plan on November 20, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 13,702 shares acquired under the Issuer's Employee Stock Purchase Plan on November 20, 2025.
F2: Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2026 Filed Mar 9, 2026 16:41 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 240,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0002006668-26-000002 · form4-03092026_080319.xml · derivative · entry 2 Carulli Michael · CIK 0002006668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2036-03-05 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 19:49 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 28,249 | $1.06 | $30,076.71 |
DisclosureSEC source: 0001415889-25-019382 · form4-07032025_110716.xml · nonDerivative · entry 1 Carulli Michael · CIK 0002006668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,146 F1 · shares: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 18:34 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 265,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001415889-25-007075 · form4-03052025_110309.xml · derivative · entry 1 Carulli Michael · CIK 0002006668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,000 Underlying: Common Stock · 265,000 shares Expires 2035-03-03 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on April 3, 2025. Read SEC document |
| September 11, 2024 Filed Sep 12, 2024 17:59 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 2,891 | $1.50 | $4,346.91 |
DisclosureSEC source: 0001415889-24-023309 · form4-09122024_090908.xml · nonDerivative · entry 1 Carulli Michael · CIK 0002006668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,395 F1 · kind: These reported shares were sold to cover the reporting person's tax obligation in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| August 13, 2024 Filed Oct 3, 2024 16:48 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | Not disclosed Strike: $1.48 | Not disclosed |
DisclosureSEC source: 0001415889-24-024624 · form4-10032024_081040.xml · derivative · entry 5 Carulli Michael · CIK 0002006668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-08-13 F7 · price: On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 75,000 shares of PMV common stock granted to the reporting person on May 12, 2023. In exchange, the reporting person received a replacement option, for 75,000 shares, having an exercise price of $1.48 per share. F8 · derivative.exercise_date: One-fourth of the shares subject to the option vest on August 13, 2025 and 1/48th vest monthly thereafter. Read SEC document |
| August 13, 2024 Filed Oct 3, 2024 16:48 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 75,000 | Not disclosed Strike: $5.70 | Not disclosed |
DisclosureSEC source: 0001415889-24-024624 · form4-10032024_081040.xml · derivative · entry 4 Carulli Michael · CIK 0002006668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-05-12 F7 · price: On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 75,000 shares of PMV common stock granted to the reporting person on May 12, 2023. In exchange, the reporting person received a replacement option, for 75,000 shares, having an exercise price of $1.48 per share. F6 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on June 12. 2023. Read SEC document |
| August 13, 2024 Filed Oct 3, 2024 16:48 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 40,805 | Not disclosed Strike: $1.48 | Not disclosed |
DisclosureSEC source: 0001415889-24-024624 · form4-10032024_081040.xml · derivative · entry 3 Carulli Michael · CIK 0002006668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,805 Underlying: Common Stock · 40,805 shares Expires 2034-08-13 F2 · price: On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 13,605 shares of PMV common stock granted to the reporting person on May 12, 2021. In exchange, the reporting person received a replacement option, for 13,605 shares, having an exercise price of $1.48 per share. F4 · price: On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 27,200 shares of PMV common stock granted to the reporting person on February 10, 2022. In exchange, the reporting person received a replacement option, for 27,200 shares, having an exercise price of $1.48 per share. F5 · derivative.exercise_date: One-third of the shares subject to the option vest on August 13, 2025 and 1/36th vest monthly thereafter. Read SEC document |
| August 13, 2024 Filed Oct 3, 2024 16:48 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 27,200 | Not disclosed Strike: $16.29 | Not disclosed |
DisclosureSEC source: 0001415889-24-024624 · form4-10032024_081040.xml · derivative · entry 2 Carulli Michael · CIK 0002006668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,200 shares Expires 2032-02-10 F4 · price: On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 27,200 shares of PMV common stock granted to the reporting person on February 10, 2022. In exchange, the reporting person received a replacement option, for 27,200 shares, having an exercise price of $1.48 per share. F3 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on March 10, 2022. Read SEC document |
| August 13, 2024 Filed Oct 3, 2024 16:48 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 13,605 | Not disclosed Strike: $28.33 | Not disclosed |
DisclosureSEC source: 0001415889-24-024624 · form4-10032024_081040.xml · derivative · entry 1 Carulli Michael · CIK 0002006668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,605 shares Expires 2031-05-12 F2 · price: On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 13,605 shares of PMV common stock granted to the reporting person on May 12, 2021. In exchange, the reporting person received a replacement option, for 13,605 shares, having an exercise price of $1.48 per share. F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2021. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 16:04 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantEmployee Stock Option (right to buy) · Derivative | 204,630 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001209191-24-001995 · doc4.xml · derivative · entry 2 Carulli Michael · CIK 0002006668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,630 Underlying: Common Stock · 204,630 shares Expires 2034-01-18 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on February 18, 2024. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 16:04 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantCommon Stock | 82,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001995 · doc4.xml · nonDerivative · entry 1 Carulli Michael · CIK 0002006668 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,286 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, all of which vest on June 30, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.